Cargando…

Acute Upper Airway Disease in Children With the Omicron (B.1.1.529) Variant of SARS-CoV-2—A Report From the US National COVID Cohort Collaborative

This cohort study uses data from the US National COVID Cohort Collaborative to evaluate upper airway infections in children during the surge of the Omicron (B.1.1.529) variant of SARS-CoV-2 in the US.

Detalles Bibliográficos
Autores principales:	Martin, Blake, DeWitt, Peter E., Russell, Seth, Sanchez-Pinto, L. Nelson, Haendel, Melissa A., Moffitt, Richard, Bennett, Tellen D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012983/ https://www.ncbi.nlm.nih.gov/pubmed/35426941 http://dx.doi.org/10.1001/jamapediatrics.2022.1110

Ejemplares similares

Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance
por: Chen, Jiahui, et al.
Publicado: (2021)

The rapid replacement of the Delta variant by Omicron (B.1.1.529) in England
por: Paton, Robert S., et al.
Publicado: (2022)

Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron)
por: Grüne, Barbara, et al.
Publicado: (2022)

Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529)
por: Chun, June Young, et al.
Publicado: (2022)

Omicron B.1.1.529 subvariant: Brief evidence and future prospects
por: Farahat, Ramadan Abdelmoez, et al.
Publicado: (2022)

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
por: Andrews, Nick, et al.
Publicado: (2022)

Omicron Sub-Lineages (BA.1.1.529 + BA.*) Current Status in Ecuador
por: Carrazco-Montalvo, Andrés, et al.
Publicado: (2022)

A comprehensive review on Covid-19 Omicron (B.1.1.529) variant
por: Manjunath, R, et al.
Publicado: (2022)

Omicron variant (B.1.1.529) of SARS-CoV-2: Threat for the elderly?
por: Chavda, Vivek P, et al.
Publicado: (2022)

The updated strategy to overcome new challenge: Omicron variant (B.1.1.529) pandemic
por: Ri, HyokJu, et al.
Publicado: (2022)

Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients
por: Spensley, Katrina J., et al.
Publicado: (2022)

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2021)

SARS-CoV-2 Omicron (B.1.1.529) Variant: No Time to Wait!
por: Rahmani, Shayan, et al.
Publicado: (2022)

A study on the effect of natural products against the transmission of B.1.1.529 Omicron
por: Alkafaas, Samar Sami, et al.
Publicado: (2023)

Detection of the Omicron (B.1.1.529) variant of SARS-CoV-2 in aircraft wastewater
por: Ahmed, Warish, et al.
Publicado: (2022)

First detection of SARS-CoV-2 variant B.1.1.529 (Omicron) in Ecuador
por: Carrazco-Montalvo, A., et al.
Publicado: (2022)

Clinical Characteristics of Omicron (B.1.1.529) Variant in Children: A Multicenter Study in Spain
por: Molina Gutiérrez, Miguel Ángel, et al.
Publicado: (2022)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura, et al.
Publicado: (2021)

Omicron variant (B.1.1.529) of SARS-CoV-2: Threat assessment and plan of action
por: Choudhary, Om Prakash, et al.
Publicado: (2022)

SARS-CoV-2 Omicron (B.1.1.529) Variant: Corticosteroids Treatment/Respiratory Coinfection
por: Elkoshi, Zeev
Publicado: (2022)

SARS-CoV-2 Omicron variant (B.1.1.529): A concern with immune escape
por: Sanyaolu, Adekunle, et al.
Publicado: (2022)

Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure
por: Reynolds, Catherine J., et al.
Publicado: (2022)

SARS-CoV-2 Omicron (B.1.1.529) Variant: A Challenge with COVID-19
por: Mohseni Afshar, Zeinab, et al.
Publicado: (2023)

A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529)
por: Lu, Yuying, et al.
Publicado: (2023)

SARS-CoV-2 (B1.1.529) Omicron variant: what has changed in the nose?
por: Ciurkiewicz, M., et al.
Publicado: (2023)

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
por: VanBlargan, Laura A., et al.
Publicado: (2022)

Detection of SARS-CoV-2 Omicron variant (B.1.1.529) infection of white-tailed deer
por: Vandegrift, Kurt J., et al.
Publicado: (2022)

Genome Sequences of 25 SARS-CoV-2 Sublineage B.1.1.529 Omicron Strains in Bangladesh
por: Bin Manjur, Omar Hamza, et al.
Publicado: (2022)

The Emergence of the Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic?
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2022)

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
por: Dejnirattisai, Wanwisa, et al.
Publicado: (2022)

Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance
por: Ren, Shi-Yan, et al.
Publicado: (2022)

The Omicron (B.1.1.529) SARS-CoV-2 variant of concern also affects companion animals
por: Sánchez-Morales, Lidia, et al.
Publicado: (2022)

Knowledge, perception, and fear among the global population towards newly evoked variant Omicron (B.1.1.529)
por: Qureshi, Ali, et al.
Publicado: (2022)

Fractional order mathematical model for B.1.1.529 SARS-Cov-2 Omicron variant with quarantine and vaccination
por: Dickson, S., et al.
Publicado: (2023)

Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases
por: Benny, Libin, et al.
Publicado: (2023)

SARS-CoV-2 B.1.1.529 (Omicron) Variant — United States, December 1–8, 2021
Publicado: (2021)

The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters
por: Abdelnabi, Rana, et al.
Publicado: (2022)

First Identification of the New Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant (B.1.1.529) in Italy
por: Micheli, Valeria, et al.
Publicado: (2022)

Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions
por: Islam, Fahadul, et al.
Publicado: (2022)

In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate
por: Touret, Franck, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ildnqatl2ervnareh1gftpbij3